RCOphth collaborate with the BMJ on latest Avastin editorial
2 November 2017
Have you read the BMJ editorial ‘Are the odds shifting against pharma in the fight for cheaper treatment for macular degeneration?’ We collaborated with the BMJ journalist to support the overall message of a much needed review of the ‘off-label’ status of Bevacizumab (Avastin), particularly in relation to the most recent news from the EU Court of Justice and the new opinion by the Advocate General. Our latest press statement outlines what this could mean for patients and the NHS. Professor Andrew Lotery, RCOphth Scientific Chair is quoted in the editorial.
Follow the conversation @RCOphth and let us know your views.
BMJ 2017; 359 doi: https://doi.org/10.1136/bmj.j5016 (Published 01 November 2017)